Remove Bioequivalency Remove Medicine Remove Regulation
article thumbnail

In the News: October Regulatory and Development Updates

Camargo

Labeling regulations prohibit reminder ads for products with boxed warnings, which the FDA requires when a drug product has very serious risks. In 2019, Foundation Medicine and Bayer Healthcare Pharmaceuticals, Inc. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.

article thumbnail

Do generics producers have what it takes to tackle complex and specialty drugs?

Pharmaceutical Technology

As more competitors enter the market, the price of a treatment goes down, explains Stanford University professor of medicine Dr. Kevin Schulman. They are sometimes referred to as hybrid medicines by the European Medicines Agency (EMA). Drugs with an AB rating meet the required bioequivalence.

Drugs 298
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovative Approaches to Generic Drug Development: Case Studies

Drug Patent Watch

The Thyroid Association’s Concerns The American Thyroid Association (ATA) had raised concerns about the FDA’s methods for determining bioequivalence between levothyroxine products[2]. It’s being used extensively to reduce development costs and accelerate access to medicines[3].

article thumbnail

Biologic Therapeutics Development, Part 2: Regulatory Pathways and Pharmacometric Analysis

Camargo

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. The regulations regarding BLAs for therapeutic biological products are included in 21 CFR parts 600 , 601 , and 610.

article thumbnail

The Importance of Regulatory Expertise in Generic Drug Development

Drug Patent Watch

Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a vital role in ensuring that generic drugs meet the necessary standards for quality, safety, and efficacy. One of the main challenges is ensuring bioequivalence with the innovator drug. EU, and other regions. ” Scientific Research Publishing , 2024.

article thumbnail

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

The Pharma Data

The US Food and Drug Administration and European Medicines Agency are currently reviewing ofatumumab for the treatment of relapsing forms of multiple sclerosis (RMS) in adults . ” These data were published in the August 6, 2020 issue of The New England Journal of Medicine. J Neurol Sci. 2003;206(2):165–71.

Trials 52
article thumbnail

The drug industry continues to dare regulation

World of DTC Marketing

Pfizer and Merck have chosen to designate a select few generic manufacturers to produce cheaper versions of their drugs through the Medicines Patent Pool (MPP). The post The drug industry continues to dare regulation appeared first on World of DTC Marketing.com. At this point, one must wonder why the U.S. About those copay cards.